<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Kommentare zu: BASEL JUNE 2 2013 &#8211; NOVARTIS TODAY PRESENTED RESULTS FROM A PIVOTAL PHASE III TRIAL OF A TREATMENT REGIMEN INCLUDING AFINITOR EVEROLIMUS TABLETS IN WOMEN WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 POSITIVE HER2&#8230;</title>
	<atom:link href="http://www.prepaid-prepaid.com/basel-june-2-2013-novartis-today-presented-results-from-a-pivotal-phase-iii-trial-of-a-treatment-regimen-including-afinitor-everolimus-tablets-in-women-with-human-epidermal-growth-factor-receptor-2-2013-06-02.html/feed" rel="self" type="application/rss+xml" />
	<link>http://www.prepaid-prepaid.com/basel-june-2-2013-novartis-today-presented-results-from-a-pivotal-phase-iii-trial-of-a-treatment-regimen-including-afinitor-everolimus-tablets-in-women-with-human-epidermal-growth-factor-receptor-2-2013-06-02.html?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=basel-june-2-2013-novartis-today-presented-results-from-a-pivotal-phase-iii-trial-of-a-treatment-regimen-including-afinitor-everolimus-tablets-in-women-with-human-epidermal-growth-factor-receptor-2</link>
	<description></description>
	<lastBuildDate></lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
</channel>
</rss>
